Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Benson Investment Management Company Inc.

Benson Investment Management Company Inc. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,149 shares of the medical research company’s stock after purchasing an additional 53 shares during the quarter. Benson Investment Management Company Inc.’s holdings in Thermo Fisher Scientific were worth $4,239,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Signet Financial Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $218,000. Courier Capital LLC raised its holdings in Thermo Fisher Scientific by 148.8% during the fourth quarter. Courier Capital LLC now owns 20,914 shares of the medical research company’s stock worth $10,880,000 after purchasing an additional 12,509 shares in the last quarter. Pallas Capital Advisors LLC lifted its position in Thermo Fisher Scientific by 2.0% in the fourth quarter. Pallas Capital Advisors LLC now owns 11,985 shares of the medical research company’s stock worth $6,235,000 after purchasing an additional 233 shares during the period. Marshall & Sullivan Inc. WA increased its position in shares of Thermo Fisher Scientific by 0.4% during the 4th quarter. Marshall & Sullivan Inc. WA now owns 8,784 shares of the medical research company’s stock valued at $4,570,000 after purchasing an additional 38 shares during the period. Finally, Sivia Capital Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 11.7% in the fourth quarter. Sivia Capital Partners LLC now owns 733 shares of the medical research company’s stock valued at $381,000 after buying an additional 77 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock valued at $25,954,465 over the last three months. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Evercore ISI dropped their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research note on Friday. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Trading Up 2.5 %

Thermo Fisher Scientific stock opened at $555.91 on Tuesday. The business’s 50-day simple moving average is $529.92 and its 200-day simple moving average is $568.10. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The firm has a market capitalization of $212.64 billion, a PE ratio of 34.85, a PEG ratio of 3.54 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.69 earnings per share. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has authorized a share repurchase plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s payout ratio is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.